LONDON--LivaNova PLC announced Vladimir Makatsaria, CEO, will present a general business update during fireside chats at Stifel, Wolfe and Piper in New York.

Aytu BioPharma (NASDAQ: AYTU) is a pharmaceutical company focused on commercializing novel therapeutics. The Company’s ...

Livanova said Monday a trial of its obstructive sleep apnea (OSA) implant met its primary safety and efficacy endpoints, positioning the company to seek approval once the analysis is complete. The ...

Read the Market Summary Here @- Global Cardiac Resynchronization Therapy (CRT) Devices Market Size Booming at Healthy CAGR of 8.4% to Touch USD 11.6 Billion by 2030 Global Cardiac Resynchronization ...

Anthony Petrone’s rating is based on several promising developments regarding LivaNova’s OSPREY study for treating obstructive sleep apnea (OSA). The company announced favorable 6-month results from ...

Needham analyst Michael Matson has maintained their bullish stance on LIVN stock, giving a Buy rating on October 31. Michael Matson has given ...

LivaNova met the primary endpoints for its OSPREY trial, Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Nerve Stimulation.

LivaNova today announced that its OSPREY trial of nerve stimulation for treating sleep apnea met its primary endpoints.

The global prosthetic heart valve market is projected to be valued at USD 13,234.9 million by 2023 and is expected to grow ...

Here are two stocks with buy rank and strong value characteristics for investors to consider today, November 7th: Nordstrom, ...

We recently published a list of 8 Most Promising Medical Stocks According to Hedge Funds. In this article, we are going to ...

LivaNova PLC ( NASDAQ:LIVN ) defied analyst predictions to release its third-quarter results, which were ahead ...